0.41

0.19% -0.0031

Lyell Immunopharma Inc (LYEL)

Overview News Price History Option Chain Financials Discussions Forecast

Lyell Immunopharma Inc stock is traded at $0.41, with a volume of 179.85K. It is down -0.19% in the last 24 hours and down -4.91% over the past month. Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Previous Close:

$0.4131

Open:

$0.4109

24h Volume:

179.85K

Relative Volume:

0.23

Market Cap:

$121.77M

Revenue:

$54,000

Net Income/Loss:

$-210.26M

P/E Ratio:

-0.519

EPS:

-0.79

Net Cash Flow:

$-159.01M

1W Performance:

+1.90%

1M Performance:

-4.91%

6M Performance:

-59.97%

1Y Performance:

-84.56%

1-Day Range:

$0.4001

$0.4182

1-Week Range:

$0.39

$0.4463

52-Week Range:

$0.39

$2.85

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name

Lyell Immunopharma Inc

Sector

Healthcare (1178)

Industry

Biotechnology (669)

Phone

650 695-0677

Address

201 HASKINS WAY, SOUTH SAN FRANCISCO

Employee

300

Twitter

Next Earnings Date

2025-03-12

Latest SEC Filings

LYEL's Discussions on Twitter

Compare LYEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYEL Lyell Immunopharma Inc	0.4123	124.51M	54,000	-210.26M	-159.01M	-0.79
ONC Beigene Ltd Adr	235.49	25.21B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	444.65	112.83B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.2632	40.72M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	605.14	62.15B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	74.01	5.75B	0	-153.72M	-103.81M	-2.00

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-11-22	Downgrade	Goldman	Buy → Neutral
Oct-17-22	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	BofA Securities	Buy
Jul-12-21	Initiated	Goldman	Buy
Jul-12-21	Initiated	JP Morgan	Overweight
Jul-12-21	Initiated	Morgan Stanley	Overweight

View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

May 14, 2025

Lyell Immunopharma: Q1 Earnings Snapshot - The Washington Post

May 14, 2025

Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline - TipRanks

May 14, 2025

May 13, 2025

Lyell Immunopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

Lyell Immunopharma Reports Clinical Progress and Financial Results for LYL314 CAR T-Cell Therapy Targeting Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq

May 13, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewswire

May 13, 2025

Breakthrough Lymphoma Treatment: Lyell's Dual-Target Therapy Achieves 94% Response Rate in Clinical Trial - Stock Titan

May 13, 2025

May 03, 2025

Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Monday - Defense World

May 03, 2025

JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 03, 2025

May 01, 2025

LYEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

May 01, 2025

Lyell Immunopharma Announces Oral Presentation of New - GlobeNewswire

May 01, 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - Stock Titan

May 01, 2025

Renaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 01, 2025